RFPClosed1View procurement thread

Evaluation of a Lead NNMT Inhibitor in Humanized Mview on SAM.gov

HEALTH AND HUMAN SERVICES, DEPARTMENT OF › NATIONAL INSTITUTES OF HEALTH OLAO

Posted Aug 4, 2026

Due Aug 19, 2026

NAICS 541714 – Research and Development in Biotechnology (except Nanobiotechnology)

Sol # 75N98026Q00941

AI Summary

• The National Institutes of Health intends to award a Firm-Fixed Price contract to GemPharmatech for research on hNNMT inhibitors under Prior Purchase Order 75N95023P00824.
• The contract involves research and development, specifically the regeneration of colonies through NNMT inhibition.
• The contract is expected to be performed at the NIH Office of Acquisitions (OxA), which is aware of GemPharmatech's capabilities in this area.

Description

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98026Q00941. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition. This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a Firm-Fixed Price on a non-competitive basis GemPharmatech LLC 11175 Flintkote AVE STE B San Diego, California 92121-1209, United States for GemPharmatech is the only known source capable of providing the required services because it developed the humanized nicotinamide N-methyltransferase (hNNMT) mouse model under prior NIH-funded work (PO 75N95023P00824) and maintains the cryopreserved sperm and breeding resources necessary to regenerate the colony. The NCATS lead NNMT inhibitor exhibits lower activity against mouse NNMT than human NNMT; therefore, evaluation in mice expressing human NNMT is required to generate scientifically relevant efficacy data. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular August 4, 2026 (iv) The associated NAICS code is 541714 ¿ Research and Development in Biotechnology (except Nanobiotechnology) and the small business size standard is 1,000 employees. This requirement is not set aside for small business.

Classification

NAICS541714

PSC CodeAN12

Contracting Office

OfficeNATIONAL INSTITUTES OF HEALTH OLAO

CityBETHESDA

StateMD

ZIP20892

Contacts

JOHNSTON, JADDUA C

jaddua.johnston@nih.gov

+1 000 000 0000

Attachments (1)

Attachment 1

Related opportunities

SURPASS Webinar and Proposers' Day InformationHEALTH AND HUMAN SERVICES, DEPARTMENT OF
UNifying Imaging with QUantum Entanglement (UNIQUE) Proposers' DayHEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sepsis Research Blood Sample Collection ServicesDEPT OF DEFENSE
Protein ENGineering (PENG)DEPT OF DEFENSE
Protein ENGineering (PENG)DEPT OF DEFENSE
Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH BiorepositoriesHEALTH AND HUMAN SERVICES, DEPARTMENT OF